Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Cagrilintide

Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

Novo Nordisk · Phase 1 · Recruiting · Enrollment 114

NCT07607587

ArmPopulationDoseWeeksEstimandWeight change
CagrilintideObesity or overweightn/rn/rn/rn/r
PlaceboObesity or overweightn/rn/rn/rn/r